Affordable treatment for common man should be the focus of all drug discovery: Dr T Ramaswami
Affordable treatment for the common man should be the focus of any drug development and the important aspect to be considered while engaging in the discovery of drugs is the effective cure for diseases.
Affordable treatment for the common man should be the focus of any drug development and the important aspect to be considered while engaging in the discovery of drugs is the effective cure for diseases, said Dr T Ramaswami, Secretary, Department of Science and Technology (DST).
He was inaugurating the short term medicinal course for industrial and academic scientists at Sri Ramachandra University in Chennai.
“We also need a greater insight into chemical biology to bring about cure for diseases that can be affordable by people at large. Building collaborative excellence among industry, academia and research institutions to bring about ultimate benefit to patients is necessary. Government is giving the highest focus for public private partnership programmes in this regard,” he added.
Sri Ramachandra University and Orchid Chemicals and Pharmaceuticals signed an memorandum of understanding (MoU) on the occasion.
K Raghavendra Rao, CMD, Orchid Chemicals said India, which is now exporting generic drugs, is well on its way to invent new drugs and produce it for the world. The MoU, he said, will provide facility for students and faculty to have internship and knowledge development at Orchid Chemicals. Further, the scientists at the company will teach and share their knowledge with medicinal chemistry students and also collaborate in joint drug development, he added.
The International Conference on Medicinal Chemistry 2013 was organized by Sri Ramachandra University and sponsored by the Department of Science and Technology, American Chemical Society, The International Union of Pure and Applied Chemistry, USA.
Dr SP Thyagarajan, dean research who signed on behalf of SRU said the medicinal chemistry course for industrial and academic scientists is based on the success of Drew University Residential School on Medicinal Chemistry, USA. It will bring together leading industrial and academic experts to present lectures on key topics. Ten international resource persons, 90 scientists from pharma companies and 30 academicians participated in the conference, he said.
Dr Balu N Balasubramaniam from Pharma Innovation Sourcing Centre, USA expressed the hope that this new collaborative knowledge will result in valuable intellectual property in the near future.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance